| Followers | 8 |
| Posts | 2087 |
| Boards Moderated | 0 |
| Alias Born | 07/31/2006 |
Friday, November 21, 2008 9:03:56 AM
Historically, perhaps that's the way it's been done. But, I think we have to leave open the possibility that pharmas are willing to do deals differently now, especially in regards to groundbreaking new technologies like NNVC's.
If your conceptualization was the set-in-stone unwavering truth going forward for all pharma deals between large established companies and small developmental stage companies like NanoViricides, then it would call into question public statements from the company over the past several months which definitely imply otherwise.
On May 28th of this year, NNVC first announced being in "Discussions with Pharma about EKC Eye Drug Candidate"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=29602527
And now, just last week, in the Fireside Chat #3 (for which the company filed an SEC 8-K document), the company characterized talks with two pharmas as follows:
"Two of the previously most interested pharmas had representatives in attendance for our talk. The tenor of our discussions have now heated up because of that presentation. Nothing like the fear of potentially losing a deal to spur people on!"
http://www.sec.gov/Archives/edgar/data/1379006/000114036108026117/ex99_1.htm
http://biz.yahoo.com/bw/081110/20081110005621.html?.v=1
These statements definitely suggest that the company believes that deals are possible over the near term, and further could be taken to imply that the company is optimistic that such a pharma deal might actually be signed in the not-too-distant future.
I think the next few weeks / months will be VERY interesting for shareholders of this company. I'm hopeful that the patience that many of us have displayed will finally be rewarded, and handsomely.
Best to you.
If your conceptualization was the set-in-stone unwavering truth going forward for all pharma deals between large established companies and small developmental stage companies like NanoViricides, then it would call into question public statements from the company over the past several months which definitely imply otherwise.
On May 28th of this year, NNVC first announced being in "Discussions with Pharma about EKC Eye Drug Candidate"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=29602527
And now, just last week, in the Fireside Chat #3 (for which the company filed an SEC 8-K document), the company characterized talks with two pharmas as follows:
"Two of the previously most interested pharmas had representatives in attendance for our talk. The tenor of our discussions have now heated up because of that presentation. Nothing like the fear of potentially losing a deal to spur people on!"
http://www.sec.gov/Archives/edgar/data/1379006/000114036108026117/ex99_1.htm
http://biz.yahoo.com/bw/081110/20081110005621.html?.v=1
These statements definitely suggest that the company believes that deals are possible over the near term, and further could be taken to imply that the company is optimistic that such a pharma deal might actually be signed in the not-too-distant future.
I think the next few weeks / months will be VERY interesting for shareholders of this company. I'm hopeful that the patience that many of us have displayed will finally be rewarded, and handsomely.
Best to you.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
